TY - JOUR

T1 - New points of departure for more global influenza vaccine use

AU - Kiseleva, Irina

N1 - Publisher Copyright: © 2020 by the author. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.

AB - Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.

KW - COVID-19 pandemic

KW - Cross protectivity

KW - Inactivated vaccines

KW - Influenza

KW - Live attenuated vaccines

KW - Next-generation vaccines

KW - Synthetic vaccines

UR - http://www.scopus.com/inward/record.url?scp=85088564536&partnerID=8YFLogxK

U2 - 10.3390/vaccines8030410

DO - 10.3390/vaccines8030410

M3 - Editorial

AN - SCOPUS:85088564536

VL - 8

SP - 1

EP - 8

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 3

M1 - 410

ER -